CataloniaBio & HealthTech is launching the seventh edition of its Biosuccess Award, an initiative that will recognise the best business milestone of 2020 in the health and life sciences sector in Catalonia. The deadline for submitting candidacies is 19 September, using this form.

The winner will receive an honorific award at the 2021 UnConference, the annual day of debates and discussions on the future of solutions for healthcare, with over 50 entrepreneurs and C-Level executives. The UnConference will be held on November in a blended format.

The panel of judges will be made up of members of the CataloniaBioHT Board ...

The pharmaceutical firm AstraZeneca and the University of Oxford have announced that their Covid-19 vaccine is safe and effective at an average of 70.4% in asymptomatic patients. Its efficacy is up to 90% depending on the dose.

Preliminary results from the Phase III clinical trial were published this week in the prestigious scientific journal The Lancet. The study involved 11,636 patients from the United Kingdom and Brazil. It is the first peer-reviewed publication of Phase III data from studies on a coronavirus vaccine. 

AZD1222 has been developed by a genetically modifying a common cold virus that affects ...

Laboratorios Rubió, a CataloniaBio & HealthTech member, has been awarded Great Place to Work® certification for its family life balance, workplace health and safety and Corporate Social Responsibility (CSR) programmes.

“We’re very proud of the Laboratorios Rubió team and believe it is very important to create an environment of trust where each person can develop their talent,” explains Joan Ramon Llonch, the company’s financial and HR director. “Great Place to Work® certification is one of the most widely recognised worldwide and is a great boost for our policies,” he adds.

The pharmaceutical company has been in business for ...

Minoryx Therapeutics, a CataloniaBio & HealthTech member, and Sperogenix Therapeutics entered into an exclusive license agreement for the development and commercialization of MIN-102 for the treatment of X-linked adrenoleukodystrophy (X-ALD) in China, Hong Kong and Macau. Currently, there is no treatment for X-ALD.

Under the terms of the agreement, Minoryx will receive an initial upfront payment and pre-defined regulatory and commercial milestone payments of up to €66-million, as well as double-digit royalties on annual net sales.

Marc Martinell, co-founder and CEO of Minoryx, says that "Sperogenix is a company with experience and capabilities in the field of rare diseases in ...